Related Experiment Video
Updated: Nov 2, 2025
Studying the Effects of Tumor-Secreted Paracrine Ligands on Macrophage Activation using Co-Culture with Permeable Membrane Supports
Published on: November 28, 2019
The tumor microenvironment and immune responses in prostate cancer patients
J T W Kwon1, R J Bryant1,2, E E Parkes1
1Department of Oncology, University of Oxford, Oxford, UK.
Abstract:
The landscape of cancer treatment has been transformed over the past decade by the success of immune-targeting therapies. However, despite sipuleucel-T being the first-ever approved vaccine for cancer and the first immunotherapy licensed for prostate cancer in 2010, immunotherapy has since seen limited success in the treatment of prostate cancer. The tumour microenvironment of prostate cancer presents particular barriers for immunotherapy. Moreover, prostate cancer is distinguished by being one of only two solid tumours where increased T cell-infiltration correlates with a poorer, rather than improved, outlook. Here, we discuss the specific aspects of the prostate cancer microenvironment that converge to create a challenging microenvironment, including myeloid-derived immune cells and cancer-associated fibroblasts. By exploring the immune microenvironment of defined molecular subgroups of prostate cancer, we propose an immunogenomic subtyping approach to single-agent and combination immune-targeting strategies that could lead to improved outcomes in prostate cancer treatment.
Insights
Prostate cancer immunotherapy faces challenges due to its unique tumor microenvironment. This study proposes an immunogenomic subtyping approach to guide immune-targeting strategies for better treatment outcomes.
Area of Science:
- Oncology
- Immunology
- Cancer Research
Background:
- Cancer immunotherapy has revolutionized treatment over the past decade.
- Despite early success with sipuleucel-T, immunotherapy has limited efficacy in prostate cancer.
- Prostate cancer's tumor microenvironment presents unique barriers to effective immunotherapy.
Purpose of the Study:
- To discuss specific aspects of the prostate cancer microenvironment that impede immunotherapy.
- To explore the immune microenvironment across defined molecular subgroups of prostate cancer.
- To propose an immunogenomic subtyping approach for improved immune-targeting strategies.
Main Methods:
- Review and discussion of the prostate cancer tumor microenvironment.
- Analysis of immune cell infiltration and its correlation with patient outlook.
- Exploration of molecular subgroups within prostate cancer.
Main Results:
- Prostate cancer exhibits a challenging microenvironment, including myeloid-derived immune cells and cancer-associated fibroblasts.
- Increased T cell infiltration in prostate cancer correlates with a poorer prognosis.
- Distinct immune microenvironments exist within different molecular subgroups of prostate cancer.
Conclusions:
- Understanding the prostate cancer immune microenvironment is crucial for therapeutic development.
- An immunogenomic subtyping approach can inform personalized single-agent and combination immunotherapy strategies.
- This approach holds potential for improving treatment outcomes in prostate cancer patients.
Related Concept Videos
02:17The Tumor Microenvironment
01:27Tumor Immunotherapy